Navigation Links
Story ideas from the Journal of Biological Chemistry
Date:1/14/2008

COX-2 inhibitors like Celecoxib have come under scrutiny lately due to adverse cardiovascular side-effects stemming from COX-2 reduction. In both fruit fly and rat models, researchers reveal another adverse effect of Celecoxib; this drug can induce arrhythmia. More interestingly, this effect is independent of the COX-2 enzyme.

Satpal Singh and colleagues tested various Celecoxib doses on the heart rate of Drosophila, a good model for human cardiac pharmacology. To their surprise, administering 3 m Celecoxib (not much higher than the plasma levels in humans taking the drug) reduced heart rate and increased beating irregularities, while 30 m was enough to stop the heart within a minute.

The surprise arises from the fact that Drosophila do not have COX-2 enzymes. Rather, Celecoxib could directly inhibit the potassium channels that help generate the electric current that drives heartbeat.

The researchers could achieve similar heart-stopping results in rat cardiac cells, whereas aspirin, another potent COX-2 inhibitor, had no effect, confirming that another mechanism is at work. The drug also inhibited rat and human potassium channels expressed in a human cell line.

Singh and colleagues point out that since these arrhythmia effects bypass COX-2, it is unclear if other COX-2 inhibitors would yield similar results. They also stress it is too early to speculate on human effects, although their results suggest Drosophila are a valuable tool to investigate other COX-2 drugs.


'/>"/>

Contact: Nick Zagorski
nzagorski@asbmb.org
American Society for Biochemistry and Molecular Biology
Source:Eurekalert  

Page: 1

Related biology news :

1. Story ideas from the Journal of Lipid Research
2. The surprising story of Charles Darwin and his homeopathic doctor
3. Story tips from the Department of Energys Oak Ridge National Laboratory, December 2007
4. Story ideas from the Journal of Lipid Research
5. Journal Sleep: Insomniacs are more likely to report a family history of the sleep disorder
6. Nanotechnology and the media: The inside story
7. Rebuilding the evolutionary history of HIV-1 unravels a complex loop
8. Story ideas from the Journal of Biological Chemistry
9. Story tips from the Department of Energys Oak Ridge National Laboratory, October 2007
10. Story ideas from Molecular & Cellular Proteomics
11. Microfossils disclose geologic history of eastern California
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Story ideas from the Journal of Biological Chemistry
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... announces that it has just released a new white paper authored by Zettar that ... speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a ...
(Date:11/14/2016)... SANTA CLARA, Calif. , Nov. 14, ... of the biometric identification market, Frost & ... Global Frost & Sullivan Award for Visionary ... leading player in the biometric identification market ... a multi-modal verification solution for instant, seamless, ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... ... of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) ... portfolio of bioprocess media products engineered to radically streamline culture processes, minimize ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/7/2016)... ... 2016 , ... ACEA Biosciences, Inc. presented today updated efficacy ... for its lead drug candidate, AC0010, at the World Conference on Lung Cancer ... the safety, antitumor activity, and recommended phase II dosage of AC0010 in T790M-postitive ...
(Date:12/7/2016)... Capital Corp. ("Zenith" or the "Company") announces webcast details for ... Annual and Special Meeting. The Zenith Annual ... December 15, 2016 at Mount Royal ... Royal Gate SW, Calgary, Alberta , commencing ... information circular, containing the matters to be considered at the ...
Breaking Biology Technology: